DE60023706D1 - Diagnose und behandlung neurorektodermaler tumore - Google Patents

Diagnose und behandlung neurorektodermaler tumore

Info

Publication number
DE60023706D1
DE60023706D1 DE60023706T DE60023706T DE60023706D1 DE 60023706 D1 DE60023706 D1 DE 60023706D1 DE 60023706 T DE60023706 T DE 60023706T DE 60023706 T DE60023706 T DE 60023706T DE 60023706 D1 DE60023706 D1 DE 60023706D1
Authority
DE
Germany
Prior art keywords
treatment
neuroectodermal tumors
chlorotoxin
fusion proteins
neurorektodermaler
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60023706T
Other languages
English (en)
Other versions
DE60023706T2 (de
Inventor
J Sontheimer
A Lyons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAB Research Foundation
Original Assignee
UAB Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAB Research Foundation filed Critical UAB Research Foundation
Publication of DE60023706D1 publication Critical patent/DE60023706D1/de
Application granted granted Critical
Publication of DE60023706T2 publication Critical patent/DE60023706T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
DE60023706T 1999-04-21 2000-04-19 Diagnose und behandlung neurorektodermaler tumore Expired - Lifetime DE60023706T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US296031 1999-04-21
US09/296,031 US6667156B2 (en) 1995-12-27 1999-04-21 Diagnosis and treatment of neuroectodermal tumors
PCT/US2000/010453 WO2000062807A1 (en) 1999-04-21 2000-04-19 Diagnosis and treatment of neuroectodermal tumors

Publications (2)

Publication Number Publication Date
DE60023706D1 true DE60023706D1 (de) 2005-12-08
DE60023706T2 DE60023706T2 (de) 2006-08-03

Family

ID=23140309

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60023706T Expired - Lifetime DE60023706T2 (de) 1999-04-21 2000-04-19 Diagnose und behandlung neurorektodermaler tumore

Country Status (10)

Country Link
US (4) US6667156B2 (de)
EP (1) EP1200123B1 (de)
JP (1) JP2002542206A (de)
CN (1) CN1377280A (de)
AT (1) ATE308340T1 (de)
AU (1) AU777209B2 (de)
CA (1) CA2365533C (de)
DE (1) DE60023706T2 (de)
ES (1) ES2253223T3 (de)
WO (1) WO2000062807A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6667156B2 (en) * 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
JP2005537234A (ja) * 2002-05-31 2005-12-08 トランスモルキュラー インコーポレイテッド クロロトキシンとの併用化学療法
ES2360519T3 (es) 2005-04-22 2011-06-06 University Of Washington Conjugado de cianina-clorotoxina y procedimiento para la visualización intraquirúrgica del cáncer.
EA016186B1 (ru) * 2005-09-26 2012-03-30 Медарекс, Инк. Человеческие моноклональные антитела к cd70 и их применение
EP2147927A3 (de) * 2006-03-31 2010-09-01 Transmolecular, Inc. Verwendung von 131I-TM-601 für die Diagnose und Behandlung von Gliomas
NZ578354A (en) * 2006-12-14 2012-01-12 Medarex Inc Antibody-partner molecule conjugates that bind cd70 and uses thereof
EP2173385A1 (de) * 2007-08-07 2010-04-14 Transmolecular, Inc. Chlorotoxine als wirkstoffträger
US20100215575A1 (en) * 2007-10-12 2010-08-26 Transmolecular, Inc. Systemic Administration of Chlorotoxin Agents for the Diagnosis and Treatment of Tumors
US8097284B2 (en) * 2007-11-13 2012-01-17 Arthur Mikaelian Polarized scorpion venom solution and a method for making polarized scorpion venom solution
AU2009246142A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
CN102438646A (zh) * 2008-05-15 2012-05-02 特兰斯莫莱库拉公司 转移性肿瘤的治疗
LT2531206T (lt) 2010-02-04 2017-09-25 Morphotek, Inc. Chlorotoksino polipeptidai ir konjugatai ir jų naudojimas
ES2811065T3 (es) 2010-05-11 2021-03-10 Hutchinson Fred Cancer Res Variantes de clorotoxina, conjugados y métodos para su utilización
US8524239B2 (en) 2010-07-09 2013-09-03 The United States of America as represented by the Secrectary, Department of Health and Human Services Photosensitizing antibody-fluorophore conjugates
CN102552943A (zh) * 2010-12-31 2012-07-11 复旦大学 一种氯代毒素修饰的肿瘤靶向磁共振造影剂及其制备方法和应用
WO2013003507A1 (en) 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
EP2928913A1 (de) 2012-12-10 2015-10-14 Fred Hutchinson Cancer Research Center Lipocalin-fusionspartner
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
US10064943B2 (en) * 2014-06-02 2018-09-04 Li-Cor, Inc. Therapeutic and diagnostic probes
CN111388672A (zh) 2014-08-08 2020-07-10 美国政府(由卫生和人类服务部的部长所代表) 在体内和在体外的靶标的光控移除
CN104877016A (zh) * 2015-04-30 2015-09-02 温州生物材料与工程研究所 折叠氯代毒素、氯代毒素变异体与折叠氯代毒素变异体及其制备工艺
US9518099B1 (en) * 2015-09-13 2016-12-13 Wenzhou Institute Of Biomaterials And Engineering Refolded chlorotoxin, chlorotoxin variant, refolded chlorotoxin variant, and preparation technology thereof
US11826399B2 (en) 2017-09-15 2023-11-28 Eisai Inc. Chlorotoxin agents and uses thereof
US11866466B2 (en) 2017-12-19 2024-01-09 Blaze Bioscience, Inc. Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002117A1 (en) * 1986-09-19 1988-03-24 Scripps Clinic And Research Foundation Monoclonal paratopic molecule directed to human ganglioside gd2
JP2975679B2 (ja) 1989-09-08 1999-11-10 ザ・ジョーンズ・ホプキンス・ユニバーシティ ヒト神経膠腫のｅｇｆ受容体遺伝子の構造変化
US5223253A (en) 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5756340A (en) 1995-05-08 1998-05-26 The Regents Of The University Of California Insect control with multiple toxins
US6667156B2 (en) * 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
AU2009246142A1 (en) * 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors

Also Published As

Publication number Publication date
EP1200123A4 (de) 2003-05-02
CA2365533A1 (en) 2000-10-26
EP1200123B1 (de) 2005-11-02
JP2002542206A (ja) 2002-12-10
US7678759B2 (en) 2010-03-16
US20120183544A1 (en) 2012-07-19
US6667156B2 (en) 2003-12-23
US20100215576A1 (en) 2010-08-26
ATE308340T1 (de) 2005-11-15
AU777209B2 (en) 2004-10-07
AU4468700A (en) 2000-11-02
US20020146749A1 (en) 2002-10-10
CN1377280A (zh) 2002-10-30
EP1200123A1 (de) 2002-05-02
CA2365533C (en) 2012-11-06
DE60023706T2 (de) 2006-08-03
ES2253223T3 (es) 2006-06-01
WO2000062807A1 (en) 2000-10-26
US20040141981A1 (en) 2004-07-22

Similar Documents

Publication Publication Date Title
DE60023706D1 (de) Diagnose und behandlung neurorektodermaler tumore
DE69329112T2 (de) Intraoperative, intravaskulare und endoskopische bestimmung und behandlung von verletzungen und tumoren
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
TR200002773T2 (tr) Alzheimer tedavisi için smilagenin ve anzurogenin-D ve bunların kullanımı.
DE69731373D1 (de) Cc-chemokinzeptor c-c ckr-5, dessen derivate und verwendungen
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
EP1955700A3 (de) Therapeutische Behandlung androgenrezeptorbedingter Leiden
BG103152A (en) Appoptosis-inducing adamantyl derivatives and their application as anticarcerogenic forms
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
NO20031323D0 (no) Peptid-baserte forbindelser
DE69622871D1 (de) Tetralin-verbindungen mit multi-drugresistenz (mdr)-aktivitat
DE29602789U1 (de) Liege, Decke o.dgl. zur therapeutischen Behandlung von Lebewesen
DE3783105D1 (de) Chinolinylaether tetrazole als mittel zur behandlung von hyperempfindlichen krankheiten.
WO2002081745A3 (en) Genes involved in osteogenesis, and methods of use
BG103261A (en) The use of 1-hydroxy-2-pyridon for the treatment of skin diseases
MXPA00010254A (es) Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
ATE293972T1 (de) Behandlung von chronischen schmerzen
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
DE69737570D1 (de) Agentien zur präsymptomatischen Detektion, Prävention und Behandlung von Brustkrebs in Menschen
BR9811402A (pt) Uso topicamente ou em outro modo administrado, de endipalene em qualquer concentração e em qualquer solvente
FI913531A0 (fi) Anvaendning av 1,2-bensopyronderivater till behandling av maligna tumoerer hos maenniskan.
NO984965L (no) Komponent B som cicatrisant
WO2004024877A3 (en) Human kininogen d3 domain polypeptide as an anti-angiogenic and anti-tumor agent

Legal Events

Date Code Title Description
8364 No opposition during term of opposition